Left to right: Caesar Garrido, President, WFH; Assad E. Haffar, Medical, Humanitarian Aid & Medical Training Director, WFH; Alain Baumann, CEO, WFH; Lydia Abad-Franch, Head of R&D and Chief Medical Officer, Sobi; Mark Skinner, Board Member, WFH USA; Glenn Pierce, Vice President, Medical, WFH; Len Valentino, President, WFH USA; Cecile Le Camus, Global Head of Hemophilia, Global Medical Affairs, Sanofi; Alaa Hamed, Global Head of Medical Affairs, Rare Diseases, Sanofi.
Left to right: Cesar Garrido, President, WFH; Assad E. Haffar, Medical, Humanitarian Aid & Medical Training Director, WFH; Alain Baumann, CEO, WFH; Lydia Abad-Franch, Head of R&D and Chief Medical Officer, Sobi; Mark Skinner, Board Member, WFH USA; Glenn Pierce, Vice President, Medical, WFH; Len Valentino, President, WFH USA; Cecile Le Camus, Global Head of Hemophilia, Global Medical Affairs, Sanofi; Alaa Hamed, Global Head of Medical Affairs, Rare Diseases, Sanofi.

Sanofi and Sobi extend partnership with the World Federation of Hemophilia Humanitarian Aid Program

The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announce the signing of a contract providing support to the WFH Humanitarian Aid Program in the form of medicine donations and financial assistance for up to 5 years.

Also available in: Français Español

The contract includes the donation of up to 100 million international units (IU) of factor therapy per year that will be distributed by the WFH Humanitarian Aid Program worldwide to developing countries. This will enable the WFH to deliver aid to people with inherited bleeding disorders across the globe.

The new signing comes as Sanofi and Sobi celebrate the tenth anniversary of answering the WFH call to action to support the global inherited bleeding disorders community through the donation of treatment products and financial aid. Between 2014 and 2024, Sanofi and Sobi provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders (cumulative number).

WFH, Sanofi and Sobi representatives signing the contract at the WFH 2025 Comprehensive Care Summit: New Developments in Bleeding Disorders and MSK, in Dubai, U.A.E.
WFH, Sanofi and Sobi representatives signing the contract at the WFH 2025 Comprehensive Care Summit: New Developments in Bleeding Disorders and MSK, in Dubai, U.A.E.

Alaa Hamed
Global Head of Medical Affairs, Rare Diseases, Sanofi

“Building on the legacy of the original ten-year, one billion IU commitment, this new agreement reaffirms Sanofi and Sobi’s dedication to creating a predictable, sustainable program that addresses unmet needs and advances the standard of care for hemophilia worldwide. Over the past decade, these contributions have expanded treatment availability and transformed patient outcomes — and this renewal ensures that impact continues for years to come.”

Lydia Abad-Franch
Head of R&D and Chief Medical Officer, Sobi

“We are immensely proud to continue our contributions to the Humanitarian Aid Program of the World Federation of Hemophilia (WFH). Since the initial pledge, over 22,000 people with hemophilia have been treated with factor donated by Sobi and Sanofi. We are thrilled to continue our partnership with the WFH and look forward to the positive impact it will have on the lives of those affected by inherited bleeding disorders.”

Cesar Garrido
President, World Federation of Hemophilia

“The contributions of Sanofi and Sobi to the WFH Humanitarian Aid Program can’t be overstated — and especially in the last ten years after they answered the WFH call to action. This new five-year contract will continue that legacy of support for the global inherited bleeding disorders community, and it will help us get closer to our shared vision of Treatment for All.”

Mark Skinner
Board Member, WFH USA

“The WFH Humanitarian Aid program is an extraordinary example of collaboration. The life-changing impact of this program is a testament to what can be achieved by working together with our industry partners. The visionary leadership of Sobi and Sanofi has provided inspiration for others in industry, hope for patients and their families, and elevated capacity of health care professionals around the world.”

To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org. To find out more about WFH USA, please visit  wfh.org/usa.

About the WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.